FROM THE TEAM
The Management Team at Cubic Health is proud to celebrate the first anniversary of Cubic Health Monthly by launching its new design and layout with this issue. We have received a great deal of positive feedback on the newsletter to date which has reinforced our commitment to bring this valuable publication to our audience. We intend to improve upon its success thus far by introducing new sections dedicated to the interests of plan sponsors, timely quick facts and metrics, case studies and interviews conducted with key individuals in the industry. It is our vision to make this a thought-provoking publication that concisely communicates insights, and current, real-world examples of drug plan management and issues faced by plan sponsors. We appreciate the time constraints of our readers and will therefore endeavour to achieve all of the above with content that is crisp and focused.
This month also marks an exciting time for us as we expand our team here at Cubic Health. We are delighted to welcome Sharon Jones as our new Drug Data Analyst. In this role, Sharon will be responsible for the management of our Cubic Health Canadian Drug Database™ which is used for our extensive analytics and reporting capabilities. She has a background working in IT related roles in the pharmaceutical industry and her experience in this area will benefit us tremendously.
We are also pleased to announce our involvement with the Global Business and Economic Roundtable on Addiction and Mental Health as Special Advisors, Group Benefits Analysis, and look forward to working with the Roundtable’s extensive network of Canadian business leaders to help address the impact of mental illness in the Canadian workplace.
We hope you enjoy this issue of Cubic Health Monthly and would encourage you to view past issues archived on our website at: http://www.cubichealth.ca/cubic_monthly.html.
Sincerely,
Kyle MacNair
Vice President, Clinical
| LATEST NEWS |
Bill 102 Passed in Ontario
Following extensive discussions and meetings with stakeholder groups, the Liberal government passed Bill 102, Transparent Drug System for Patients Act, 2006 on Monday, June 19, with a number of amendments to the original legislation proposed April 13. Groups such as the Ontario Pharmacists’ Association (OPA) and other key stakeholders will continue to work closely with the Ministry of Health and Long-Term Care to define the Regulations to the legislation in the upcoming months before Bill 102 comes into effect October 1, 2006.
Click here to read more...
|
Cubic Health Teams Up With the Global Business and Economic Roundtable on Addiction and Mental Health
Cubic Health is pleased to announce its involvement with the Global Business and Economic Roundtable on Addiction and Mental Health (“Roundtable”) as Special Advisors, Group Benefits Analysis. In this capacity, Cubic Health will use their proprietary systems and reporting applications to help the Roundtable further research and quantify the impact of mental illness in the workplace for Canadian employers from a drug utilization perspective.
Click here to read more...
|
| DRUG & DISEASE NEWS |
Fighting the Allergy Season: Considerations for Plan Sponsors
The coming of spring and summer carries with it a sharp increase in the number of people suffering from allergy symptoms. People with “seasonal allergy” disorders most often experience symptoms affecting the eyes and nose. For some facts and figures about the incidence rates and costs associated with seasonal allergies, please see the “Quick Facts” section of this issue.
Click here to read more...
|
NOC Watch:
The Advent of Oral Chemotherapy Agents
Is Generic Norvasc™ Coming Soon?
Click here to read more...
|
| FOR THE PLAN SPONSOR |
Cubic Health Presents To Plan Sponsors In Toronto On The Practical Applications Of Quantitative Analysis
On June 15, Chris von Heymann and Mike Sullivan of Cubic Health addressed an audience of plan sponsors, consultants and insurance industry stakeholders at the annual Rogers Media Solutions in Drug Plan Management conference held in Toronto. The presentation focused on the practical applications of quantitative analysis for plan sponsors concerned with current or future trends in their drug plan experience.
Click here to read more...
|
|
|
 |
June 2006
Issue No. 13 |
 |
QUICK FACTS
The Impact of Allergy Season |
|
|
Number of Canadian adults suffering from seasonal allergies requiring some form of drug treatment: 1 in 6
|
|
In a survey of Canadian adults about allergy symptoms:
Albertans reported the highest rate of allergy development at 57%
Manitoba and Saskatchewan tied for the lowest rate at 44%.
Of those surveyed that suffered from allergies, 62% indicated it affected their day-to-day life, including sleep patterns and ability to work.
|
|
In the United States,
estimated cost of treating seasonal allergies (including medications and physician billing): over $1.1 billion
estimated cost due to loss of productivity and absenteeism: $4.6 billion
Read more...
|
|
|
|
 |
|
